ACROBiosystems products

Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein.

Trastuzumab, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication. Trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein.

Name:B-cell maturation protein. Target Synonym:B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen.

Name:Receptor protein-tyrosine kinase erbB-2. Target Synonym:EC 2.7.10.1,HER-2/Neu,Herstatin,HER-2,TKR1,Receptor, ErbB-2,V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2,Neuroblastoma/Glioblastoma Derived Oncogene Homolog,C-Erb B2/Neu Protein,CD340 Antigen,EC:2.7.10.1,EC 2.7.10,MLN 19,CD340,Tyrosine kinase-type cell surface receptor HER2,Receptor tyrosine-protein kinase erbB-2,ERBB2,MLN19,Proto-oncogene Neu,Erb-B2 Receptor Tyrosine Kinase 2,V-E.

Protein aggregation is a major pathological feature of neurodegenerative diseases such as Alzheimer`s disease (AD), Parkinson`s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington`s disease (HD). Under pathological conditions, Tau, Amyloid beta, alpha-synuclein, TDP-43, Huntingtin and other proteins integrate into a wide array of undesirable structures, ranging from oligomers and prefibrillar assemblies to highly ordered aggregates. The fibrillar structure represents a rapid growth phase of protein aggregation as these fibrils are “active” and rapidly recruit monomers for elongation. In additions, these fibrils randomly break into shorter fragments that could act as “seeds”, which transmits to other cells and independently recruits monomers to form novel fibrils.